Searchable abstracts of presentations at key conferences in endocrinology

ea0082wc5 | Workshop C: Disorders of the thyroid gland | SFEEU2022

Two case reports of suspected thyroid assay interference

Miler Emma , Chipchase Allison , Ahluwalia Rupa

Case 1: A 17-year-old female was referred to the endocrinology outpatients due to abnormal thyroid function tests (TFTs) (as below) detected on routine monitoring for Thyroxine replacement therapy. Following exclusion of pregnancy, possibilities of assay interference due to heterophilic antibodies as well as thyroid hormone resistance were considered. Repeat analysis was arranged at two laboratories using different methods. Results were concordant, excluding assay interference...

ea0086p245 | Neuroendocrinology and Pituitary | SFEBES2022

An investigation into discrepancies between serum insulin-like growth factor 1 (IGF-1) concentrations and clinical presentation in the assessment of acromegaly

Miler Emma , McMurray Susanne , McArdle Nicholas , Ahluwalia Rupa , Chipchase Allison

Background: The suitability of serum insulin-like growth factor 1 (IGF-1) reference ranges (RR) used locally (manufacturer-derived), were raised as a clinical concern. IGF-1 levels above the RR were reported in patients displaying no clinical signs or symptoms of acromegaly, and in whom growth hormone suppression tests were negative. No analytical issue was evident, and quality performance indicators were satisfactory.Methods: A review of all serum IGF-1...

ea0094p118 | Reproductive Endocrinology | SFEBES2023

An audit of elevated serum testosterone in females with discrepant results

Miler Emma , Tam Trevor , Amjad Wajiha , Ahluwalia Rupa , Chipchase Allison

Background: While investigating hyperandrogenism in women, local laboratory policy dictates adult females with a serum testosterone of >3.5 nmol/l should be confirmed with an alternative method to exclude interference by cross-reacting substances. Patients who were on testosterone replacement or had a previous result in the same year were excluded. We explore the biochemical investigation of discrepant testosterone in females.<strong...

ea0094op6.2 | Bone and Calcium | SFEBES2023

Measuring FGF23 in patients treated with burosumab

Piec Isabelle , Chipchase Allison , Miler Emma , Ramachandran Hari , Webb Emma , Fraser William D

Burosumab has become available as a treatment for children with X-linked hypophosphatemia (XLH) and is a recombinant fully human IgG1 against FGF23. By binding to the active FGF23, burosumab inhibits its effect and symptoms (growth retardation, rickets, enthesiopathy, low phosphate) may improve, however, not in all children. Concomitantly paediatricians are keen to measure FGF23, in treated children, to avoid overtreatment with burosumab, associated with potential calcificatio...